What is Losartankalium/HCT Xiromed?
Losartankalium/HCT Xiromed contains a combination of Losartankalium/HCT Xiromed. Hydrochlorothiazide (Losartankalium/HCT Xiromed) is a thiazide diuretic (water pill) that helps prevent your body from absorbing too much salt, which can cause fluid retention. Losartan (Losartankalium/HCT Xiromed) is an angiotensin II receptor antagonist. Losartan (Losartankalium/HCT Xiromed) keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow.
Losartankalium/HCT Xiromed is used to treat high blood pressure (hypertension). It is also used to lower the risk of stroke in certain people with heart disease.
Losartankalium/HCT Xiromed may also be used for purposes not listed in this medication guide.
Losartankalium/HCT Xiromed indications
Hypertension
Losartankalium/HCT Xiromed® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Losartan (Losartankalium/HCT Xiromed) and Hydrochlorothiazide (Losartankalium/HCT Xiromed).
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients.
Losartankalium/HCT Xiromed may be administered with other antihypertensive agents.
Hypertensive Patients With Left Ventricular Hypertrophy
Losartankalium/HCT Xiromed is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients.
How should I use Losartankalium/HCT Xiromed?
Use Losartankalium/HCT Xiromed as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Losartankalium/HCT Xiromed. Talk to your pharmacist if you have questions about this information.
- Take Losartankalium/HCT Xiromed by mouth with or without food.
- Drinking extra fluids while you are taking Losartankalium/HCT Xiromed is recommended. Check with your doctor for instructions.
- Losartankalium/HCT Xiromed may increase the amount of urine or cause you to urinate more often when you first start taking it. To keep this from disturbing your sleep, try to take your dose before 6 pm.
- If you take cholestyramine or colestipol, ask your doctor or pharmacist how to take it with Losartankalium/HCT Xiromed.
- Continue to take Losartankalium/HCT Xiromed even if you feel well. Do not miss any doses.
- If you miss a dose of Losartankalium/HCT Xiromed, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Losartankalium/HCT Xiromed.
Uses of Losartankalium/HCT Xiromed in details
Use: Labeled Indications
Hypertension: Management of hypertension.
Hypertension with left ventricular hypertrophy: To reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (LVH). Evidence suggests that this benefit does not apply to black patients.
Losartankalium/HCT Xiromed description
Each tablet contains Losartan (Losartankalium/HCT Xiromed) potassium 50 or 100 mg and Hydrochlorothiazide (Losartankalium/HCT Xiromed) 12.5 mg.
Losartan (Losartankalium/HCT Xiromed) Potassium: Losartan (Losartankalium/HCT Xiromed) potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol monopotassium salt.
Its empirical formula is C22H22ClKN6O.
Losartan (Losartankalium/HCT Xiromed) potassium is a white to off-white free-flowing crystalline powder with a molecular weight of 461.01. It is freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents eg, acetonitrile and methyl ethyl ketone.
Oxidation of the 5-hydroxymethyl group on the imidazole ring results in the active metabolite of Losartan (Losartankalium/HCT Xiromed).
Hydrochlorothiazide (Losartankalium/HCT Xiromed): Hydrochlorothiazide (Losartankalium/HCT Xiromed) is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide.
Its empirical formula is C7H8ClN3O4S2.
It is a white, or practically white, crystalline powder with a molecular weight of 297.74, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.
Losartankalium/HCT Xiromed dosage
Hypertension
The usual starting dose of Losartankalium/HCT Xiromed is 50/12.5 (Losartan (Losartankalium/HCT Xiromed) 50 mg/Hydrochlorothiazide (Losartankalium/HCT Xiromed) 12.5 mg) once daily. The dosage can be increased after 3 weeks of therapy to a maximum of 100/25 (Losartan (Losartankalium/HCT Xiromed) 100 mg/Hydrochlorothiazide (Losartankalium/HCT Xiromed) 25 mg) once daily as needed to control blood pressure.
Initiate a patient whose blood pressure is not adequately controlled with Losartan (Losartankalium/HCT Xiromed) 50 mg monotherapy with Losartankalium/HCT Xiromed 50/12.5 once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, the dosage may be increased to two tablets of Losartankalium/HCT Xiromed 50/12.5 once daily or one tablet of Losartankalium/HCT Xiromed 100/25 once daily.
Initiate a patient whose blood pressure is not adequately controlled with Losartan (Losartankalium/HCT Xiromed) 100 mg monotherapy with Losartankalium/HCT Xiromed 100/12.5 (Losartan (Losartankalium/HCT Xiromed) 100 mg/Hydrochlorothiazide (Losartankalium/HCT Xiromed) 12.5 mg) once daily. If blood pressure remains uncontrolled after about 3 weeks of therapy, increase the dose to two tablets of Losartankalium/HCT Xiromed 50/12.5 once daily or one tablet of Losartankalium/HCT Xiromed 100/25 once daily.
Initiate a patient whose blood pressure is inadequately controlled with Hydrochlorothiazide (Losartankalium/HCT Xiromed) 25 mg once daily, or is controlled but who experiences hypokalemia with this regimen, on Losartankalium/HCT Xiromed 50/12.5 once daily, reducing the dose of Hydrochlorothiazide (Losartankalium/HCT Xiromed) without reducing the overall expected antihypertensive response. Evaluate the clinical response to Losartankalium/HCT Xiromed 50/12.5 and, if blood pressure remains uncontrolled after about 3 weeks of therapy, increase the dose to two tablets of Losartankalium/HCT Xiromed 50/12.5 once daily or one tablet of Losartankalium/HCT Xiromed 100/25 once daily.
Hypertensive Patients with Left Ventricular Hypertrophy
In patients whose blood pressure is not adequately controlled on 50 mg Losartan (Losartankalium/HCT Xiromed) potassium, initiate treatment with Losartankalium/HCT Xiromed 50/12.5. If additional blood pressure reduction is needed, increase the dose to Losartankalium/HCT Xiromed 100/12.5, followed by Losartankalium/HCT Xiromed 100/25. For further blood pressure reduction add other antihypertensives.
Losartankalium/HCT Xiromed interactions
See also:
What other drugs will affect Losartankalium/HCT Xiromed?
Agents Increasing Serum Potassium
Coadministration of Losartan (Losartankalium/HCT Xiromed) with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.
Lithium
Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of angiotensin II receptor antagonists or thiazide diuretics. Monitor lithium levels in patients receiving Losartankalium/HCT Xiromed and lithium.
Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors
Losartan (Losartankalium/HCT Xiromed) Potassium
In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including Losartan (Losartankalium/HCT Xiromed)) may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Losartan (Losartankalium/HCT Xiromed) and NSAID therapy.
The antihypertensive effect of angiotensin II receptor antagonists, including Losartan (Losartankalium/HCT Xiromed), may be attenuated by NSAIDs, including selective COX-2 inhibitors.
Hydrochlorothiazide (Losartankalium/HCT Xiromed)
The administration of a non-steroidal anti-inflammatory agent including a selective COX-2 inhibitor can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when Losartankalium/HCT Xiromed and non-steroidal anti-inflammatory agents including selective COX-2 inhibitors are used concomitantly, observe closely to determine if the desired effect of the diuretic is obtained.
In patients receiving diuretic therapy, coadministration of NSAIDs with angiotensin receptor blockers, including Losartan (Losartankalium/HCT Xiromed), may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Hydrochlorothiazide (Losartankalium/HCT Xiromed), Losartan (Losartankalium/HCT Xiromed), and NSAID therapy.
Dual Blockade Of The Renin-Angiotensin System (RAS)
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
The Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) trial enrolled 1448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 to 89.9 mL/min), randomized them to lisinopril or placebo on a background of Losartan (Losartankalium/HCT Xiromed) therapy and followed them for a median of 2.2 years. Patients receiving the combination of Losartan (Losartankalium/HCT Xiromed) and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end-stage renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group.
Closely monitor blood pressure, renal function, and electrolytes in patients on Losartankalium/HCT Xiromed and other agents that affect the RAS.
Do not coadminister aliskiren with Losartankalium/HCT Xiromed in patients with diabetes. Avoid use of aliskiren with Losartankalium/HCT Xiromed in patients with renal impairment (GFR < 60 mL/min).
The Use Of Hydrochlorothiazide (Losartankalium/HCT Xiromed) With Other Drugs
When administered concurrently, the following drugs may interact with thiazide diuretics :
Antidiabetic drugs (oral agents and insulin) — dosage adjustment of the antidiabetic drug may be required.
Cholestyramine and colestipol resins — Absorption of Hydrochlorothiazide (Losartankalium/HCT Xiromed) is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the Hydrochlorothiazide (Losartankalium/HCT Xiromed) and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively. Stagger the dosage of Hydrochlorothiazide (Losartankalium/HCT Xiromed) and the resin such that Hydrochlorothiazide (Losartankalium/HCT Xiromed) is administered at least 4 hours before or 4 to 6 hours after the administration of the resin.
Losartankalium/HCT Xiromed side effects
See also:
What are the possible side effects of Losartankalium/HCT Xiromed?
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Losartan (Losartankalium/HCT Xiromed) potassium-Hydrochlorothiazide (Losartankalium/HCT Xiromed) has been evaluated for safety in 858 patients treated for essential hypertension and 3889 patients treated for hypertension and left ventricular hypertrophy. Most adverse reactions have been mild and transient in nature and have not required discontinuation of therapy. In controlled clinical trials, discontinuation of therapy due to clinical adverse events was required in only 2.8% and 2.3% of patients treated with the combination and placebo, respectively.
In these double-blind controlled clinical trials, adverse reactions occurring in greater than 2% of subjects treated with Losartan (Losartankalium/HCT Xiromed)-Hydrochlorothiazide (Losartankalium/HCT Xiromed) and at a greater rate than placebo were: back pain (2.1% vs 0.6%), dizziness (5.7% vs 2.9%), and upper respiratory infection (6.1% vs 4.6%).
The following additional adverse reactions have been reported in clinical trials with Losartankalium/HCT Xiromed and/or the individual components:
Blood and the lymphatic system disorders: Anemia, aplastic anemia, hemolytic anemia, leukopenia, agranulocytosis.
Metabolism and nutrition disorders: Anorexia, hyperglycemia, hyperuricemia, electrolyte imbalance including hyponatremia and hypokalemia.
Psychiatric disorders: Insomnia, restlessness.
Nervous system disorders: Dysgeusia, headache, migraine, paraesthesias.
Eye disorders: Xanthopsia, transient blurred vision.
Cardiac disorders: Palpitation, tachycardia.
Vascular disorders: Dose-related orthostatic effects, necrotizing angiitis (vasculitis, cutaneous vasculitis).
Respiratory, thoracic and mediastinal disorders: Nasal congestion, pharyngitis, sinus disorder, respiratory distress (including pneumonitis and pulmonary edema).
Gastrointestinal disorders: Dyspepsia, abdominal pain, gastric irritation, cramping, diarrhea, constipation, nausea, vomiting, pancreatitis, sialoadenitis.
Hepato-biliary disorders: Jaundice (intrahepatic cholestatic jaundice).
Skin and subcutaneous tissue disorders: Rash, pruritus, purpura, toxic epidermal necrolysis, urticaria, photosensitivity, cutaneous lupus erythematosus.
Musculoskeletal and connective tissue disorders: Muscle cramps, muscle spasm, myalgia, arthralgia.
Renal and urinary disorders: Glycosuria, renal dysfunction, interstitial nephritis, renal failure.
Reproductive system and breast disorders: Erectile dysfunction/impotence.
General disorders and administration site conditions: Chest pain, edema/swelling, malaise, fever, weakness.
Investigations: Liver function abnormalities.
Cough
Persistent dry cough has been associated with ACE-inhibitor use and in practice can be a cause of discontinuation of ACE-inhibitor therapy. Two prospective, parallel-group, double-blind, randomized, controlled trials were conducted to assess the effects of Losartan (Losartankalium/HCT Xiromed) on the incidence of cough in hypertensive patients who had experienced cough while receiving ACE-inhibitor therapy. Patients who had typical ACE-inhibitor cough when challenged with lisinopril, whose cough disappeared on placebo, were randomized to Losartan (Losartankalium/HCT Xiromed) 50 mg, lisinopril 20 mg, or either placebo (one study, n=97) or 25 mg Hydrochlorothiazide (Losartankalium/HCT Xiromed) (n=135). The double-blind treatment period lasted up to 8 weeks. The incidence of cough is shown in Table 1 below.
| |||
| Study 1* | HCTZ | Losartan (Losartankalium/HCT Xiromed) | Lisinopril |
| Cough | 25% | 17% | 69% |
| Study 2† | Placebo | Losartan (Losartankalium/HCT Xiromed) | Lisinopril |
| Cough | 35% | 29% | 62% |
These studies demonstrate that the incidence of cough associated with Losartan (Losartankalium/HCT Xiromed) therapy, in a population that all had cough associated with ACE-inhibitor therapy, is similar to that associated with Hydrochlorothiazide (Losartankalium/HCT Xiromed) or placebo therapy.
Cases of cough, including positive re-challenges, have been reported with the use of Losartan (Losartankalium/HCT Xiromed) in postmarketing experience.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Losartankalium/HCT Xiromed. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.
Digestive: Hepatitis has been reported rarely in patients treated with Losartan (Losartankalium/HCT Xiromed).
Hematologic: Thrombocytopenia.
Hypersensitivity: Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported rarely in patients treated with Losartan (Losartankalium/HCT Xiromed); some of these patients previously experienced angioedema with other drugs including ACE inhibitors. Vasculitis, including Henoch-Schönlein purpura, has been reported with Losartan (Losartankalium/HCT Xiromed). Anaphylactic reactions have been reported.
Musculoskeletal: rhabdomyolysis
Skin: Erythroderma
Losartankalium/HCT Xiromed contraindications
See also:
What is the most important information I should know about Losartankalium/HCT Xiromed?
Hypersensitivity to Losartan (Losartankalium/HCT Xiromed), sulphonamide-derived substances (as Hydrochlorothiazide (Losartankalium/HCT Xiromed)) or to any of the excipients of Losartankalium/HCT Xiromed.
Therapy resistant hypokalemia or hypercalcemia; severe hepatic impairment; cholestasis and biliary obstructive disorders; refractory hyponatremia; symptomatic hyperuricemia/gout; 2nd and 3rd trimester of pregnancy; lactation; severe renal impairment (ie, creatinine clearance <30 mL/min); anuria.
Excipient: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Losartankalium/HCT Xiromed.
Use in lactation: It is not known whether Losartan (Losartankalium/HCT Xiromed) is excreted in human milk. However, Losartan (Losartankalium/HCT Xiromed) is excreted in the milk of lactating rats. Because no information is available regarding the use of Losartan (Losartankalium/HCT Xiromed) during breastfeeding, Losartan (Losartankalium/HCT Xiromed) is not recommended and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while nursing a newborn or preterm infant.
Thiazides pass into human milk and may inhibit lactation. Because of the potential for adverse effects on the nursing infant, Losartan (Losartankalium/HCT Xiromed)/HCTZ is contraindicated during breastfeeding.
Active ingredient matches for Losartankalium/HCT Xiromed:
Hydrochlorothiazide/Losartan in Netherlands.
List of Losartankalium/HCT Xiromed substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Losartankalium/HCT Teva (Netherlands) | |
| Losartankalium/hydrochloorthiazide A (Netherlands) | |
| Losartankalium/Hydrochloorthiazide Apotex (Netherlands) | |
| Losartankalium/hydrochloorthiazide Auro (Netherlands) | |
| Losartankalium/Hydrochloorthiazide Bluefish (Netherlands) | |
| Losartankalium/hydrochloorthiazide Farmaprojects (Netherlands) | |
| Losartankalium/hydrochloorthiazide IPCA (Netherlands) | |
| Losartankalium/Hydrochloorthiazide Mylan (Netherlands) | |
| Losartankalium/hydrochlorthiazid Actavis (Denmark) | |
| Losartankalium/hydrochlorthiazid Amneal (Denmark) | |
| Losartankalium/hydrochlorthiazid Krka (Denmark) | |
| Losartankalium/Hydrochlorthiazid Medical Valley (Denmark) | |
| Losartankalium/hydrochlorthiazid Teva (Denmark) | |
| Losartar-H (India) | |
| Losartar-H Losartan K , Hydrochlorothiazide TAB / 10 (Shrrishti HC) | $ 0.60 |
| 10's (Shrrishti HC) | $ 0.60 |
| LOSARTAR-H tab 10's (Shrrishti HC) | $ 0.60 |
| Losartas HT (Peru) | |
| Losartas HT Hydrochlorothiazide 12.5mg, Losartan K 50mg TAB / 7 | $ 0.69 |
| Losartas HT Tablet (Intas Pharmaceuticals Ltd) | $ 0.11 |
| Losarteg HCT (El Salvador) | |
| Losartic HC (Slovenia) | |
| Losartic Plus (Croatia (Hrvatska), Serbia) | |
| Losartil-Plus (Turkey) | |
| Losasis-H | |
| Losasis-H 50mg/12.5mg Tablet (CHS Formulations) | $ 0.08 |
| Losastal-H Tablet | |
| Losastal-H Tablet (Stallion Laboratories Pvt Ltd) | $ 0.08 |
| LOSASUN HT | |
| LOSASUN HT TABLET 1 strip / 10 tablets each (Sunij Pharma Pvt Ltd) | $ 0.35 |
| LOSATAN H | |
| LOSATAN H TABLET 1 strip / 10 tablets each (Biochem Pharmaceutical Industries) | $ 0.60 |
| Losatan Hz (Bangladesh) | |
| LOSATEC H | |
| LOSATEC H 50 MG/12.5 MG TABLET 1 strip / 10 tablets each (RPG Life Sciences Ltd) | $ 1.00 |
| Losatec-H (India) | |
| Losatec-H Capsule/ Tablet / 12.5mg-50mg / 10 units (RPG LS) | $ 0.64 |
| Losatec-H Losartan K 50mg, Hydrochlorothiazide 12.5mg TAB / 10 (RPG LS) | $ 0.83 |
| 10's (RPG LS) | $ 0.83 |
| LOSATEC-H tab 10's (RPG LS) | $ 0.83 |
| Losatrix Comp (Finland, Sweden) | |
| LOSATRUST H | |
| LOSATRUST H TABLET 1 strip / 10 tablets each (Centaur Pharmaceuticals Pvt Ltd) | $ 0.76 |
| Losatrust-H (India) | |
| Losatrust-H Capsule/ Tablet / 12.5mg-50mg / 10 units (Centaur (Sankalp)) | $ 0.43 |
| Losatrust-H Losartan 50mg, Hydrochlorothiazide 12.5mg TAB / 10 (Centaur (Sankalp)) | $ 0.47 |
| 10's (Centaur (Sankalp)) | $ 0.52 |
| Losatrust-H Losartan 50mg, Hydrochlorothiazide 12.5mg FC-TAB / 10 (Centaur (Sankalp)) | $ 0.52 |
| LOSATRUST-H film-coated tab 10's (Centaur (Sankalp)) | $ 0.52 |
| LOSAVAS H | |
| LOSAVAS H TABLET 1 strip / 10 tablets each (Orchid Chemicals & Pharmaceuticals Ltd) | $ 0.88 |
| Losavik -H | |
| Losavik -H Losartan K 50mg, Hydrochlorothiazide 12.5mg TAB / 100 | $ 6.63 |
| Losavik-H (India) | |
| 100's (Anvik Biotech) | $ 6.63 |
See 1294 substitutes for Losartankalium/HCT Xiromed | |
References
- DailyMed. "AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "LOSARTAN POTASSIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "losartan". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Losartankalium/HCT Xiromed are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Losartankalium/HCT Xiromed. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
